OBJECTIVE: To investigate the potential role of mucosal intestinal myofibroblasts (IMFs) in HIV and associated fibrosis in gut-associated lymphoid tissue. DESIGN: Profibrotic changes within the secondary lymphoid organs and mucosa have been implicated in failed immune reconstitution following effective combination antiretroviral therapy (cART). Microbial translocation is believed to be sustaining these systemic inflammatory pathways. IMFs are nonprofessional antigen-presenting cells with both immunoregulatory and mesenchymal functions that are ideally positioned to respond to translocating microbial antigen. METHODS: Duodenal biopsies, obtained from patients naive to cART, underwent trichrome staining and were examined for tissue growth factor-beta (TGF-β) expression. Combined immunostaining and second harmonic generation analysis were used to determine IMF activation and collagen deposition. Confocal microscopy was performed to examine IMF activation and Toll-like receptor (TLR)4 expression. Finally, primary IMF cultures were stimulated with lipopolysaccharide to demonstrate the expression of the inflammatory biomarkers. RESULTS: The expression of the fibrosis-promoting molecule, TGF-β1, is significantly increased in duodenal biopsies from HIV patients naïve to cART, and negatively correlated with subsequent peripheral CD4(+) recovery. The increase in TGF-β1 coincided with an increase in collagen deposition in the duodenal mucosa in the tissue area adjacent to the IMFs. We also observed that IMFs expressed TLR4 and had an activated phenotype since they were positive for fibroblast activation protein. Finally, stimulation of IMFs from HIV patients with TLR4 resulted in significantly increased expression of profibrotic molecules, TGF-β1, and interleukin-6. CONCLUSION: Our data support the hypothesis that activated IMFs may be among the major cells contributing to the profibrotic changes, and thus, the establishment and maintenance of systemic inflammation interfering with immune reconstitution in HIV patients.
OBJECTIVE: To investigate the potential role of mucosal intestinal myofibroblasts (IMFs) in HIV and associated fibrosis in gut-associated lymphoid tissue. DESIGN: Profibrotic changes within the secondary lymphoid organs and mucosa have been implicated in failed immune reconstitution following effective combination antiretroviral therapy (cART). Microbial translocation is believed to be sustaining these systemic inflammatory pathways. IMFs are nonprofessional antigen-presenting cells with both immunoregulatory and mesenchymal functions that are ideally positioned to respond to translocating microbial antigen. METHODS: Duodenal biopsies, obtained from patients naive to cART, underwent trichrome staining and were examined for tissue growth factor-beta (TGF-β) expression. Combined immunostaining and second harmonic generation analysis were used to determine IMF activation and collagen deposition. Confocal microscopy was performed to examine IMF activation and Toll-like receptor (TLR)4 expression. Finally, primary IMF cultures were stimulated with lipopolysaccharide to demonstrate the expression of the inflammatory biomarkers. RESULTS: The expression of the fibrosis-promoting molecule, TGF-β1, is significantly increased in duodenal biopsies from HIVpatients naïve to cART, and negatively correlated with subsequent peripheral CD4(+) recovery. The increase in TGF-β1 coincided with an increase in collagen deposition in the duodenal mucosa in the tissue area adjacent to the IMFs. We also observed that IMFs expressed TLR4 and had an activated phenotype since they were positive for fibroblast activation protein. Finally, stimulation of IMFs from HIVpatients with TLR4 resulted in significantly increased expression of profibrotic molecules, TGF-β1, and interleukin-6. CONCLUSION: Our data support the hypothesis that activated IMFs may be among the major cells contributing to the profibrotic changes, and thus, the establishment and maintenance of systemic inflammation interfering with immune reconstitution in HIVpatients.
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: Timothy W Schacker; Jason M Brenchley; Gregory J Beilman; Cavan Reilly; Stefan E Pambuccian; Jodie Taylor; David Skarda; Matthew Larson; Daniel C Douek; Ashley T Haase Journal: Clin Vaccine Immunol Date: 2006-05
Authors: Collin L Ellis; Zhong-Min Ma; Surinder K Mann; Chin-Shang Li; Jian Wu; Thomas H Knight; Tammy Yotter; Timothy L Hayes; Archana H Maniar; Paolo V Troia-Cancio; Heather A Overman; Natalie J Torok; Anthony Albanese; John C Rutledge; Christopher J Miller; Richard B Pollard; David M Asmuth Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: Christopher deFilippi; Robert Christenson; Jessica Joyce; Elli A Park; Ashley Wu; Kathleen V Fitch; Sara E Looby; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Janet Lo Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Talia Sainz; Sergio Serrano-Villar; Surinder Mann; Zhong-Min Ma; Netanya S Utay; Corbin G Thompson; Tae-Wook Chun; Angela D Kashuba; Basile Siewe; Anthony Albanese; Paolo Troia-Cancio; Elizabeth Sinclair; Anoma Somasunderam; Tammy Yotter; Santiago Moreno; Richard B Pollard; Alan Landay; Christopher J Miller; David M Asmuth Journal: AIDS Date: 2019-12-01 Impact factor: 4.177
Authors: Leslie R Cockerham; Steven A Yukl; Kara Harvill; Ma Somsouk; Sunil K Joshi; Elizabeth Sinclair; Teri Liegler; Rebecca Hoh; Sophie Lyons; Peter W Hunt; Adam Rupert; Irini Sereti; David R Morcock; Ajantha Rhodes; Claire Emson; Marc K Hellerstein; Jacob D Estes; Sharon Lewin; Steven G Deeks; Hiroyu Hatano Journal: Pathog Immun Date: 2017-08-02
Authors: Sophie Seang; Anoma Somasunderam; Maitreyee Nigalye; Ma Somsouk; Timoty W Schacker; Joyce L Sanchez; Peter W Hunt; Netanya S Utay; Jordan E Lake Journal: Pathog Immun Date: 2017-06-21
Authors: David M Asmuth; Corbin G Thompson; Tae-Wook Chun; Zhong-Min Ma; Surinder Mann; Talia Sainz; Sergio Serrano-Villar; Netanya S Utay; Juan Carlos Garcia; Paolo Troia-Cancio; Richard B Pollard; Christopher J Miller; Alan Landay; Angela D Kashuba Journal: J Infect Dis Date: 2017-10-17 Impact factor: 5.226
Authors: F A Tobolowsky; N Wada; O Martinez-Maza; L Magpantay; S L Koletar; F J Palella; T T Brown; J E Lake Journal: PLoS One Date: 2018-01-30 Impact factor: 3.240